0.40Open0.40Pre Close47 Volume1.17K Open Interest9.00Strike Price1.63KTurnover108.39%IV11.71%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.3462Delta0.2605Gamma27.75Leverage Ratio-0.0297Theta0.0006Rho9.61Eff Leverage0.0048Vega
Anavex Life Sciences Stock Discussion
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL) announced it will present new long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial for blarcamesine in early Alzheimer's disease at the J.P. Morgan 2025 Healthcare Conference. The presentation will showcase data from up to 144 weeks of continuous treatm...
hmmmmm 🤔 looks very similar throughout the market starting at 3 pm
No comment yet